Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

A malaria vaccine tested in more than 2,000 Mozambique children cut the risk of developing the disease by 30 percent and lowered the incidence of life-threatening episodes by 58 percent, according to One NIH official is quoted as saying this is “a major advance.”

These are the first early results (published today in The Lancet; registration required) from the largest pediatric malaria vaccine trial done in Africa and are the first to show some benefit of a malaria vaccine for kids. This is hope for a field that hasn’t had much success in developing a vaccine for a disease that kills 3000 children each day. (My colleague Erika Jonietz wrote about new malaria vaccines, including this one, a few months back.)

It won’t be until the end of the decade at the earliest that we might see a malaria vaccine approved. Let’s just hope that GlaxoSmithKline, the drug company that co-developed this vaccine and has said it’s committed to making this vaccine a reality, will actually follow through on its promise, considering how unlucrative the vaccine business is. It’s doubtful the company will be able to supply the vaccine affordably to everyone who needs it without help from richer nations.

0 comments about this story. Start the discussion »

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me